CRISPR Therapeutics (NASDAQ:CRSP) Director Sells 14,514 Shares of Stock

Key Points

• Director Simeon George sold 14,514 CRISPR Therapeutics shares at an average price of $49.63, generating approximately $720,330 and reducing his direct holdings by 48.38% to 15,486 shares.
• CRSP shares fell 4.4% to $49.25, near the company’s $44.12 52-week low. The biotechnology firm reported a quarterly loss of $0.94 per share on $10.18 million in revenue, and analysts expect a full-year loss.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $65.75 average price target, while institutional investors own 69.2% of the company.

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director Simeon George sold 14,514 shares of the firm's stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the sale, the director directly owned 15,486 shares in the company, valued at approximately $768,570.18. This trade represents a 48.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CRISPR Therapeutics Trading Down 4.4%

Shares of CRSP stock traded down $2.27 during mid-day trading on Friday, reaching $49.25. The stock had a trading volume of 1,517,934 shares, compared to its average volume of 1,747,018. The stock's 50-day moving average price is $55.07 and its two-hundred day moving average price is $53.24. CRISPR Therapeutics AG has a 52-week low of $44.12 and a 52-week high of $75.06. The firm has a market capitalization of $4.76 billion, a PE ratio of -10.35 and a beta of 1.76. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The firm had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. Equities analysts expect that CRISPR Therapeutics AG will post -4.48 earnings per share for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Cyndeo Wealth Partners LLC boosted its holdings in shares of CRISPR Therapeutics by 6.1% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 7,406 shares of the company's stock valued at $410,000 after acquiring an additional 428 shares during the last quarter. AdvisorNet Financial Inc grew its stake in shares of CRISPR Therapeutics by 25.5% in the third quarter. AdvisorNet Financial Inc now owns 10,673 shares of the company's stock worth $590,000 after acquiring an additional 2,170 shares during the period. GAMMA Investing LLC grew its stake in shares of CRISPR Therapeutics by 92.0% in the third quarter. GAMMA Investing LLC now owns 1,246 shares of the company's stock worth $69,000 after acquiring an additional 597 shares during the period. Green Alpha Advisors LLC raised its holdings in shares of CRISPR Therapeutics by 1.8% during the third quarter. Green Alpha Advisors LLC now owns 56,786 shares of the company's stock valued at $3,141,000 after purchasing an additional 982 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of CRISPR Therapeutics by 43.6% during the third quarter. Farther Finance Advisors LLC now owns 11,426 shares of the company's stock valued at $632,000 after purchasing an additional 3,470 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on CRSP. Citizens Jmp reaffirmed a "market outperform" rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Citigroup reissued a "market outperform" rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a research note on Thursday. HC Wainwright restated a "buy" rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Finally, UBS Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday. They set a "neutral" rating and a $52.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $65.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG NASDAQ: CRSP is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients' cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.